Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy

Targeted therapies, such as endocrine therapies (ET), can exert selective pressure on cancer cells and promote adaptations that confer treatment resistance. In this study, we show that ET resistance in breast cancer drives radiation resistance through reprogramming of DNA repair pathways. We also sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Udden, S. M. Nashir, Baek, GuemHee, Pandey, Kamal, Vidal, Chantal, Liu, Yulun, Rahimi, Asal S., Kim, D. Nathan, Nwachukwu, Chika R., Mani, Ram S., Alluri, Prasanna G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873388/
https://www.ncbi.nlm.nih.gov/pubmed/36693944
http://dx.doi.org/10.1038/s41698-023-00348-1
Descripción
Sumario:Targeted therapies, such as endocrine therapies (ET), can exert selective pressure on cancer cells and promote adaptations that confer treatment resistance. In this study, we show that ET resistance in breast cancer drives radiation resistance through reprogramming of DNA repair pathways. We also show that pharmacological bromodomain and extraterminal domain inhibition reverses pathological DNA repair reprogramming in ET-resistant breast tumors and overcomes resistance to radiation therapy.

Ejemplares similares